OVERVIEW
There are currently nine branded biologics, multiple TNF biosimilars and two oral janus kinase (JAK) inhibitors approved for the treatment of rheumatoid arthritis (RA) in the European Union. With the recent introduction of several agents with alternative MOAs, a multitude of more affordable biosimilars, and the approvals of two JAK inhibitors, the EU RA treatment landscape is in a state flux. Additionally, a pipeline ripe with line-extensions and new biologics and small molecules is due to bring further disruption.

The RealTime Dynamix™: Rheumatoid Arthritis (EU) report series provides a detailed and timely look at current and future trends in the RA market and the effects of the future shifting landscape. The bi-annual releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated bi-annually. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the rheumatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

SAMPLE & METHODOLOGY
The report is based on an online survey of ~250 rheumatologists practicing in the EU5. Rheumatologists meet screening criteria including time in practice, percent of professional time spent in clinical practice (vs. teaching or research), minimum number of RA patients, and minimum number of RA patients on biologic agents. Surveys are programmed in the local language.

KEY QUESTIONS ANSWERED
• How is the current and near-term landscape for the RA biologic market evolving? How does this differ by country?
• How are biosimilar agents impacting the biologic market?
• How are the JAK inhibitors, Olumiant and Xeljanz, expected to perform?
• How much of an advantage will Olumiant have being the first JAK to the market?
• Is there a need for a second IL-6 inhibitor, and where will Kevzara fit in the treatment protocol for RA?
• How will the new entrants to the IL-6 and JAK classes impact both existing class dynamics and the overall sequencing of treatments?
• What are the critical issues for companies to address for a successful launch into the RA market in each of the EU5 countries?
• What are the critical opportunities and barriers to growth for each brand and class?
• Which brands are preferred for different patient types?
• What is the rheumatologist’s perception of late stage pipeline assets and how do they anticipate incorporating these assets into their RA treatment?